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Abstract
The physiological mechanisms that regulate reactive hyperemia are not fully understood. We postulated that the
endothelial P2Y1 receptor that release vasodilatory factors in response to ADP might play a vital role in the regulation of
coronary flow. Intracoronary flow was measured with a Doppler flow-wire in a porcine model. 2-MeSADP (10
j5 M),
ATP (10
j4 M) or UTP (10
j4 M) alone or as co-infusion with a selective P2Y1 receptor blocker, MRS 2179 (10
j3 M) was
locally delivered through the tip of a coronary angioplasty balloon. In separate pigs the coronary artery was occluded with
the balloon for 10 min. During the first and tenth minutes of coronary ischemia, 2.5 ml of MRS 2179 (10
j3 M) was
delivered distal to the occlusion in 8 pigs, 10 pigs were used as controls. MRS 2179 fully inhibited the 2-MeSADP-
mediated coronary flow increase (P G 0.05) with no effect on UTP, indicating selective P2Y1 inhibition. ATP-mediated
flow increase was significantly inhibited by MRS 2179. During reactive hyperemia following coronary occlusion, flow
increased by nearly sevenfold. MRS 2179, however, reduced the post-ischemic hyperemia by a mean of 46% during the
period 1–2.5 min following balloon deflation (P G 0.05), which corresponds to peak velocity flow during reperfusion. In
conclusion, MRS 2179, a selective P2Y1 receptor blocker, significantly reduces the increased coronary flow caused both
by 2-MeSADP and reactive hyperemia in coronary arteries. Thus, ADP acting on the endothelial P2Y1 receptor may play
a major role in coronary flow during post-ischemic hyperemia.
Abbreviations: ADP–adenosine diphosphate; ATP–adenosine triphosphate; EDHF–endothelium-derived hyperpolarizing
factor; LAD–left anterior descending artery; NO–nitrous oxide; SMC–smooth muscle cells; UTP–uridine triphosphate
Introduction
During a coronary artery occlusion, the area of the heart
supplied by the artery is deprived of its blood supply. Upon
reperfusion there is a dramatic rise in coronary blood flow,
far above the baseline flow prior to the occlusion [1]. The
mechanism for this enormous increase in flow during
reactive hyperemia is somewhat of an enigma because the
incurred oxygen debt does not in itself justify the flow
increase [2]. Several factors have been implicated, and the
mechanism is now thought to be multifactorial in origin.
Several substances (adrenalin, ADP/ATP, substance P,
bradykinin and to some extent also adenosine) activate
receptors on the endothelium of the coronary artery,
stimulating release of nitrous oxide (NO), prostaglandins
and endothelium-derived hyperpolarizing factor (EDHF),
that in turn cause relaxation of the underlying smooth
muscle cells (SMC) [2–6]. Adenosine stimulates SMC
relaxation directly by acting on specific receptors (mainly
A2A) on the SMC [3]. K
+
ATP channels are regulated by the
cellular metabolic state and when they are activated the
SMC is hyperpolarized, which causes relaxation. Thus,
the K
+
ATP channels could provide a link between intracel-
lular ischemia and vasorelaxation. Indeed, the K
+
ATP
channel inhibitor glibenclamide has been shown to inhibit
a part of the reactive hyperemia [7, 8]. The effect of
adenosine, prostaglandins, and NO during reactive hyper-
emia in coronary vessels has been studied with use of
specific receptor blockers (NOS inhibitors, adenosine
receptor antagonists, and cyclo-oxygenase inhibitors), and
it has been found that there still exists an unaccountable
rise in blood flow during reperfusion [7, 9–12].
A role for P2 receptors in reactive hyperemia has been
proposed by Burnstock and Rongen, but no direct exper-
imental evidence has yet been published probably because
of the previous lack of specific antagonists [13–15]. In the
previous studies, it was demonstrated that adenosine and
even more potently ATP administered through intracoro-
nary injection and infusion can cause a pharmacologic
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emia [13–17].
The extracellular purine nucleotides ATP and ADP,
which regulate vascular tone and blood pressure by
stimulating P2 receptors, are released in the heart during
ischemia from cardiac myocytes, endothelial cells, red
blood cells, platelets and sympathetic nerves [3, 13, 14,
18]. P2Y1 receptors are found in abundance on the
endothelial cells of the coronary vessel wall and can
promote hyperemia in response to selective P2Y1 agonists
[3, 13, 14, 19]. Research has shown that P2Y1 receptors
promote smooth muscle relaxation through both NO and
EDHF [3–6]. Recently, a selective P2Y1 receptor inhibitor,
MRS 2179, has become available [4, 5, 20], facilitating
further exploration of these effects.
We therefore decided to test the hypothesis that a
selective blockade of coronary P2Y1 receptors could
diminish the post-ischemic hyperemia compared to con-
trols in a porcine model.
Materials and methods
Animals
A total of 27 healthy domestic pigs of both sexes weighing
25 kg were fasted overnight with free access to water and
were premedicated with azaperone (Stresnil Vet., Leo;
Helsingborg, Sweden), 2 mg/kg i.m. 30 min before the
procedure. After induction of anesthesia with thiopental
5–25 mg/kg (Pentothal; Abbott, Stockholm, Sweden), the
animals were orally intubated with cuffed endotracheal
tubes. A slow infusion of 1.25 2l/ml Fentanyl (Fentanyl;
Pharmalink, Stockholm, Sweden) in Ringer’s acetate
solution was started at a rate of 1.5 ml/min and adjusted as
needed. Mechanical ventilation was then established with a
Siemens-Elema 300B ventilator in the volume-controlled
mode. Initial settings were: Respiratory rate of 15 min, tidal
volume of 10 ml/kg, and positive end-expiratory pressure of
5c mH 2O. Minute volume was subsequently adjusted in
order to obtain normocapnia (35–40 mm Hg). The animals
were ventilated with a mixture of dinitrous oxide (70%)
and oxygen (30%). Anesthesia was complemented with
small intermittent doses of 5 mg meprobamat (Mebumal;
DAK, Copenhagen, Denmark) and thiopental (Pentothal;
Abbott, Stockholm, Sweden), if needed.
A 6 F introducer sheath (Onset; Cordis, Miami, Florida,
USA) was inserted into the surgically exposed left femoral
artery. The side port of the introducer was connected to a
pressure transducer and balanced to atmospheric pressure
with zero reference at the mid-axillary level for continu-
ously monitoring of the arterial pressure. A three-lead ECG
was displayed on the same monitor as the pressure curve
(78342 A, Hewlett and Packard, Boeblingen, Germany).
A 6 F introducer sheath (Onset; Cordis, Miami, Florida,
USA) was inserted into the surgically exposed left carotid
artery upon which a 6F JL 3.5 Wiseguidei (Boston
Scientific Scimed, Maple Grove, Minnesota, USA) was
inserted into the left main coronary artery and 10,000 IU of
Heparin was administered. An angiogram was obtained
using8–10mlofthe contrastmedium Omnipaquei300 mg
I
j/ml (Nycomed, Oslo, Norway) to ensure correct posi-
tioning of the catheter. The catheter was used to place a
0.014-inch, 12-MHz pulsed Doppler flow velocity trans-
ducer (Jometrics Flowire, Jomed NV) into the mid-portion
of the left anterior descending artery (LAD) and a 0.014-
inch PT choicei guidewire (Boston Scientific Scimed,
Maple Grove, Minnesota, USA) into the distal portion of
the LAD. A 3.0  20 mm over-the-wire Mavericki
angioplasty balloon (Boston Scientific Scimed, Maple
Grove, Minnesota, USA) was then positioned in the mid
portion of the LAD but proximal to the flow velocity
transducer followed by the withdrawal of the PT choice
guidewire. Continuous coronary velocity flow profiles
were displayed and recorded using the Doppler flow wire
connected to a FloMap monitor (Cardiometrics, Mountain
View, California, USA). Flow was measured in units of
average peak velocity (APV) in centimetres per second. All
radiological procedures were performed in an experimental
catheterization laboratory (Shimadzu, Kyoto, Japan).
The lumen of the angioplasty balloon was connected to an
infusion pump, Asena CC (Alavis Medical, Bristol, UK). The
infusion pump was initially used to infuse Ringer’s acetate
solution and NaCl (9%) at rates of 0.5, 1, 2, 4 and 6 ml/
min in the LAD through the inner lumen of the
angioplasty balloon catheter. At an infusion rate of 2 ml/
min or less, there were no effects on blood flow in the LAD.
In five pigs, 2-MeSADP (10
j5 M) at 1 ml/min was
infused and Flomap measurements were performed.
2-MeSADP (10
j5 M) was then infused with MRS 2179
(10
j3 M) at a rate of 1 ml/min. To test the effect of MRS
2179 on ATP, 5 ml of ATP (10
j4 M) was delivered into
the LAD (n=9). Following the 30-min washout period,
5 ml of ATP (10
j4 M) together with 5 ml of MRS 2179
(10
j3 M) was delivered into the LAD. The order of the
ATP and the combination of ATP + MRS2179 infusions
was altered randomly. To test the effect of MRS 2179 on
P2Y2/4 receptors, 5 ml of UTP (10
j4 M) was delivered into
the LAD (n=3). Following the 30-min washout period,
5m lo fU T P( 1 0
j4 M) together with 5 ml of MRS 2179
(10
j3 M) was delivered into the LAD. The 2-MeSADP
infusions were delivered for 2 min while the ATP and
UTP infusions were delivered for only 1 min.
To test the effect of MRS 2179 on reactive hyperemia,
an occlusion of the LAD was achieved with inflation of the
angioplasty balloon for a period of 10 min. During the first
and tenth minutes of coronary ischemia, 2.5 ml of
MRS2179 (10
j3 M) was delivered distal to the occlusion
in the LAD in eight pigs. A total of 10 pigs were used as
controls. Reactive hyperemia was only measured once in
each pig. Blood gas analysis was performed at baseline and
at 1 and 10 min following reperfusion in the 18 pigs treated
with balloon inflation.
Protocol
At baseline, measurements of blood pressure, pulse and
APV were performed. Blood pressure and pulse were
60 G. K. Olivecrona et al.measured continuously with coronary blood flow and APV
analyzed once every 10 s. A blood gas analysis was
performed at baseline and at 1 and 5 min post-reperfusion.
Reagents
Unless otherwise stated, drugs were purchased from Sigma
(USA).
Ethics
The Ethics Committee of Lund University approved the
project.
Calculation and statistics
Calculations and statistics were performed using the
GraphPad Prism 3.02 software. Values are presented as
meanTS.E.M. Statistical significance was accepted when
PG0.05 (two-tailed test). One-way analysis of variance
(ANOVA) test followed by Dunnett’s multiple comparison
test was used.
Results
During infusion with isotonic crystalloid (Ringer’s acetate
solution) and NaCl (9%) in the LAD there was a slight
flow increase with infusion rates at or above 3 ml/min, but
not at flow G 2 ml/min. In Figure 1, Ringer’s acetate
solution was infused at 1 ml/min.
When the ADP analogue 2-MeSADP (10
j5 M) was
infused at a rate of 1 ml/min, flow in the LAD increased
significantly (PG0.05; Figure 1). However, the effects of
2-MeSADP (10
j5 M) on blood flow in the LAD was fully
inhibited when infused together with the P2Y1 receptor
antagonist MRS 2179 (10
j3 M) at a rate of 1 ml/min,
(n=5, PG0.05) (Figure 1). Following a 30-min washout
period, the dilatations to 2-MeSADP without MRS 2179
could be repeated with similar results as the initial
dilatation (data not shown). MRS 2179 alone did not have
any effect on basal coronary flow.
ATP delivered selectively in the LAD caused an increase
of flow in the LAD by a factor of 5. When ATP was
delivered together with MRS 2179 there was significant
reduction of flow in the LAD by approximately 50%
(n=9), demonstrating that a major portion of the ATP-
induced flow is mediated through its degradation-product
ADP acting on P2Y1 receptors (Figure 2).
UTP delivered selectively in the LAD caused an increase
of flow in the LAD by a factor of 3.5. When UTP was
delivered together with MRS 2179 there was no difference
in increased flow in the LAD, demonstrating the selectivity
of MRS 2179 (n=3, Figure 3).
Post-ischemic flow in the LAD increased nearly
sevenfold in the 10 pigs treated with balloon inflation
alone in the LAD (n=10). In contrast, a significant 46%
reduction of flow in the early phase (1–2.5 min following
balloon deflation corresponding to the period of the fastest
flow during post-ischemic hyperemia) was observed in the
Figure 1. Ringer’s acetate solution infused into coronary vessels of pigs,
open circles, did not alter coronary flow from baseline. Infusion of
2-MeSADP increased flow by 300%, closed circles. The 2-MeSADP-
mediated flow increase was essentially aborted by simultaneous infusion
of MRS 2179, closed squares. Data are expressed as percentage of
baseline flow (100%) and shown as means T S.E.M., *P G0.05,
**PG0.01 (n=5).
Figure 2. Intracoronary infusion of ATP increased flow in pig coronary
arteries by a factor of 5, closed circles. The ATP-mediated flow increase
was then reduced by 50% during simultaneous intracoronary administra-
tion of MRS 2179, open circles. Data are expressed as percentage of
baseline flow (100%) and shown as means T S.E.M., *P G0.05,
**PG0.01 (n=9).
Figure 3. Intracoronary infusion of UTP increased flow, in pig coronary
arteries, approximately by a factor of four, closed circles. The UTP-
mediated flow increase was not blocked by MRS2179, open circles. Data
are expressed as percentage of baseline flow (100%) and shown as
means T S.E.M., P=NS(n=3).
P2Y1 receptor mediates reactive hyperemia 61eight pigs receiving bolus doses of MRS 2179 (PG0.05,
Figure 4). During infusions of NaCl, 2-MeSADP and MRS
2179, there were no significant differences in blood
pressure or pulse rate between the groups at the analyzed
time intervals (Figure 5). There was no difference in basal
coronary flow rates between the control and MRS 2179
groups (10.2 T 4.9 and 11.3 T 3.7 cm/s, mean T S.D.,
P=NS). The flow rates returned to initial values at the
end of the experiments.
The analyzed blood-gas samples of the 18 pigs in the
occlusion/reperfusion group showed no statistical differ-
ence between the pigs receiving MRS2179 and the group
treated as controls (Table 1).
Discussion
The main finding in these experiments is that the selective
P2Y1 blocker MRS 2179 significantly reduces the early
peak flow by 46% in coronary reactive hyperemia in pigs.
This is supported by the flow increase caused by the
selective P2Y1 agonist 2-MeSADP, which could be
completely blocked by MRS 2179.
The mechanism of reactive hyperemia is still not
completely understood but appears to be multifactorial in
origin. Investigations of the effects of adenosine [9, 21,
22], prostaglandins [23–26], and K
+
ATP channels [7, 8, 11,
27–29] and the role of NO [11, 12, 30, 29–33], acting alone
or in combinations with each other, have been performed.
Earlier research on post-ischemic reactive hyperemia in the
heart has been performed both in vivo in large animals, as
well as in Langendorf models in rodents. However, using
rodents in a Langendorf model has its inherent drawbacks
due to the lack of ATP release from red blood cells in
response to ischemia. In large animals, in vivo models have
shown that adenosine by itself contributes to about 1/3 of
the reactive hyperemia with NO contributing slightly less
[9, 10]. Saito et al. [9] showed that adenosine did not
contribute to peak reactive hyperemia but instead reduced
payment of flow debt following peak flow. Morrison et al.
[34] have shown in recent work that the contribution of
adenosine to reactive hyperemia occurred 3 min after
reperfusion and thus well after peak flow in an A2A
receptor knockout mouse model. Similar findings were
seen using a selective A2A antagonist [11]. Thus, adenosine
plays an important role in post-ischemic reactive hyper-
emia in the heart but seems to contribute to flow only well
after peak flow has occurred.
K
+
ATP channels in smooth muscle cells have also been
implemented as a major contributor to reactive hyperemia
in the heart. The experiments with K
+
ATP channel blockers
(glibenclamide) have mainly been assessed in Langendorf
models in rodent hearts and to some extent in large in vivo
models. In these experiments, K
+
ATP channel blockers
significantly reduced reactive hyperemia [7, 11]. Interest-
ingly, K
+
ATP channel blockers did not seem to affect
reactive hyperemia in the forearm [35]. Prostaglandins
have been found to contribute only marginally to reactive
hyperemia, both in the heart and in the forearm [7, 26].
Recent research has demonstrated that red blood cells
release ATP in response to ischemia [36, 37]. ATP is then
Figure 4. The ensuing reactive hyperemia following a 10-min coronary
occlusion was measured as a nearly sevenfold increase of flow (closed
circles). Infusion of MRS 2179 reduced the early post-ischemic flow
increase by 46%. Data are expressed as percentage of baseline (100%) and
shown as means T S.E.M., *P G 0.05 (n = 8–10 pigs).
Figure 5. a) In the pigs subjected to coronary occlusion blood pressure
was measured at baseline, during ischemia and during reperfusion. There
was no statistical difference in the either diastolic or systolic blood
pressure between controls (n = 10, open symbols) or pigs treated with
MRS 2179 (n = 8, closed symbols). Mean diastolic and systolic blood
pressure are expressed as T S.E.M., P = NS. b) In pigs subjected to
coronary occlusion the heart rate was measured at baseline, during
ischemia and during reperfusion. There was no statistical difference in
heart rate between controls, open circles, or pigs treated with MRS 2179,
closed circles. Data are mean heart rate expressed as T S.E.M., P = NS.
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vascular endothelium at the site of the P2Y1 receptor.
Selective blockers of the P2Y1 receptors have recently
become available [20], allowing us to test the role of P2Y1
receptors during post-ischemic reactive hyperemia. The
porcine in vivo model in our experiment was chosen
because the presence of whole blood and a live model was
essential. The use of angioplasty Fover-the-wire` balloons
allowed for precision in attaining both accurate and
localised induction of ischemia, and delivery of infusions.
The physiological alterations induced by open chest
experiments could thus be avoided. The infusion of
Ringer’s acetate solution at the same rate as later infusions
of 2-MeSADP and MRS 2179 did not alter measurements
of flow from baseline. The selective P2Y1 receptor agonist
2-MeSADP induced a predicted increase in flow, which
could be completely abolished by co-infusion of 2-
MeSADP and the selective P2Y1 receptor blocker MRS
2179. In contrast, UTP, which activates P2Y2/4 receptors,
stimulated a flow increase that was unaffected by MRS
2179, demonstrating the selectivity for P2Y1 receptors of
MRS 2179. To test the contribution of P2Y1 receptors to
post-ischemic–hyperemia, the LAD was occluded, and
MRS 2179 was infused into the ischemic portion of the
heart supplied by the LAD. The 46% reduction of peak
flow achieved during reactive hyperemia indicates that
P2Y1 receptors are of major importance as an activator of
endothelium-derived smooth muscle cell relaxing factors
such as NO and EDHF. NO and EDHF has been shown to
mediate a major part of early reactive hyperemia [8, 10–
12], and both are released by ADP acting on P2Y1
receptors [3–6]. The K
+
ATP channel inhibitor glibenclamide
blocks the remaining early reactive hyperemia [11].
Interestingly, glibenclamide is also an inhibitor of P2Y1-
mediated vasodilatation [6]. It is therefore possible that a
part of the hyperemia blocked by glibenclamide is
stimulated by ADP via endothelial P2Y1 receptors and
that glibenclamide in part acts downstream of the P2Y1
activation and not only after intracellular metabolic
regulation of K
+
ATP channels.
The time profile of the mediators of reactive hyperemia
is highly interesting. Previous studies using adenosine
deaminase, theophylline [9], selective A2A antagonists
[11], or A2A knockout mice [34], have shown that
adenosine mediates the late phase of reactive hyperemia.
This adenosine is probably derived from degradation by
ecto-nucleotidases of the ADP that we now demonstrate
mediates a major part of the early peak phase. We would
like to propose that ATP is released during ischemia from
red blood cells; cardiomyocytes, endothelial cells and
platelets, and that ATP could mediate an even earlier part
of the hyperemia (Figure 6). This has not been tested yet
due to the lack of selective antagonists. (The presence of
ATP- and UTP-responsive endothelial P2Y2/4 receptors has
been demonstrated before [3] and was confirmed here by
the hyperemic effect of UTP.) ATP is then degraded to
ADP, which mediates peak hyperemia via endothelial
P2Y1 receptors, followed by degradation of ADP to
adenosine resulting in late-phase hyperemia mediated via
A2A receptors on SMC (Figure 6).
Table 1. Arterial blood-gas analysis of pigs with occlusion and reperfusion of a coronary vessel treated with MRS 2179 (n=8) or used as controls
(n=10).
Baseline 1 min reperfusion 5 min reperfusion
Control MRS2179 Control MRS2179 Control MRS2179
pH 7.47T0.05 7.49T0.03 7.45T0.07 7.48T0.03 7.46T0.06 7.47T0.05
pCO2 5.4T0.8 5.3T0.5 5.6T1.0 5.3T0.4 5.3T0.7 5.3T0.6
pO2 46.8T19.0 43.7T16.3 40.6T14.6 46.1T20.2 35.4T3.9 36.3T4.4
Na
+ 132T2 135T1 133T2 134T1 132T2 135T1
K
+ 3.5T0.2 3.6T0.3 3.4T0.2 3.7T0.3 3.4T0.3 3.6T0.1
Hb 89T89 2 T39 1 T89 3 T48 8 T59 2 T3
O2 97.1T0.2 97.2T0.2 97.9T1.5 97.2T0.2 97.1T0.1 97.2T0.2
HCO3 29.0T1.9 30.0T0.3 28.6T1.6 29.4T0.3 28.2T1.3 29.2T0.7
Base excess 5.6T0.8 6.1T0.2 4.9T0.8 5.6T0.3 5.1T0.8 5.3T0.4
Samples were collected at baseline and at 1 and 5 min following reperfusion. There was no statistical differences between pigs treated with MRS 2179 or
pigs used as controls. Data are expressed as mean T S.E.M., P = NS.
Figure 6. This figure illustrates a hypothesis of smooth muscle cells
relaxation in response to accumulation of purinergic substrates in coronary
vessels following post-ischemic reperfusion. Red blood cells, heart
myocytes, endothelial cells, platelets and sympathetic nerves release
ATP during hypoxia. ATP may contribute to the very early reactive
hyperemia, although this has not been proven due to lack of specific
antagonists. ATP is quickly degraded to ADP which stimulates P2Y1
receptors on the endothelium, thus initiating the peak flow during the early
phase of reactive hyperaemia, as demonstrated in the present study. ADP
is then degraded to adenosine that stimulates A2A-receptors and thus
maintains reactive hyperemia during the mid- to late phase [7–10].
P2Y1 receptor mediates reactive hyperemia 63In conclusion, our experiments suggest that ADP
stimulating P2Y1 receptors mediates a major part of peak
reactive hyperemia in the heart. Inhibition of the P2Y1
receptor could potentially attenuate the reperfusion injury
incurred during primary angioplasty in the setting of acute
myocardial infarction [38].
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